Mr. Lu, the founder of Biosensors International Group Ltd, was its chairman and CEO from its inception to 2008. He retained his leadership position as chairman of the Group since January 2008 until November 2016.
Mr. Lu has more than 30 years’ experience in the medical industry. Prior to starting Biosensors in 1990, Mr. Lu established Asia-based operations for the Medical Division of Gould Inc in Tokyo in 1978. In 1986, he participated in a management-led leveraged buyout of the division from Gould and he continued as president of the Asia-Pacific division through 1988. Mr. Lu took the company to IPO in Nasdaq and it was subsequently sold to British Oxygen Corporation. He served as president of Asia-Pacific with British Oxygen until 1990.
Mr. Lu is active in both international and local medical arena as an entrepreneurial angel investor. Mr. Lu is a General Partner at Majuven Pte Ltd; Foundry Singapore and a venture partner for medical sector at Vertex Venture Management Pte Ltd. With SPRING, Mr. Lu collaborates with Accuron Technologies Ltd (a wholly- owned subsidiary of Temasek) through the Sector Specific Accelerator program.
Yoh-Chie serves on the board of directors for Earlens, Moximed, Ivantis, Visterra, and Innoventures.
Dr. Carolyn Ng is a Principal of Vertex Ventures HC. At Vertex, Carolyn is responsible for evaluating and driving venture investments across biotechnology, medical devices, and health tech fields. Oncology scientist by background, she is passionate about innovation that impacts patients’ lives. Splitting time across the San Francisco Bay Area and Singapore, she plays an active role in facilitating cross border collaborations and business development for Vertex’s healthcare portfolio companies. Prior to joining Vertex, Carolyn was a Strategy Consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm where she led global strategic projects for clientele comprised of the top 20 global pharmaceutical companies.
Carolyn currently serves on the board of directors for Obsidian Therapeutics, and is a board observer for Bicycle Therapeutics, Visterra, Earlens and Nuvaira.
Carolyn Ng holds a PhD in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS PhD Scholarship. She is an inventor and patent holder of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma. She also holds a BS (Pharmacy) (First Class Honours) degree from the National University of Singapore.
Lori Hu is a Principal at Vertex Ventures HC. Ms. Hu joined in 2015 to help establish the US office and manages global healthcare investments in biotech, medical devices and digital health. Before Vertex, Lori was an Associate Director for Business Development at Bristol-Myers Squibb, identifying and executing licensing and partnership transactions. She has also worked with SR One, the corporate venture capital arm of GlaxoSmithKline. Previously, she was a strategy consultant at Accenture, advising biopharmaceutical clients on strategic projects across the US and Asia.
Lori serves on the Board of Directors for Palleon Pharma, and is a board observer for Ivantis, Moximed and Kona.
Lori graduated with an MBA from The Wharton School, and MA in International Studies from the University of Pennsylvania where she was a Leonard Lauder Fellow. She also holds a BSE in Biomedical Engineering from Duke University. She is based in the Bay Area.